Literature DB >> 26728571

Clinical and haematological risk factors for cerebral macrovasculopathy in a sickle cell disease newborn cohort: a prospective study.

Julie Sommet1,2,3, Corinne Alberti1,2,3, Nathalie Couque4, Suzanne Verlhac5, Zinedine Haouari6,7, Damir Mohamed3, Martine François8, Florence Missud6,7, Laurent Holvoet6,7, Monique Elmaleh5, Ghislaine Ithier6,7, André Denjean9,10, Jacques Elion4,11, André Baruchel6,12, Malika Benkerrou1,2,6,7.   

Abstract

Children with sickle cell disease (SCD) have a significant vascular morbidity, especially cerebral macrovasculopathy (CV), detectable by transcranial Doppler. This study aimed to identify risk factors for CV using longitudinal biological and clinical data in a SCD newborn cohort followed at the Robert Debre Reference centre (n = 375 SS/Sβ(0) ). Median follow-up was 6·8 years (2677 patient-years). Among the 59 children presenting with CV, seven had a stroke. Overall, the incidence of CV was 2·20/100 patient-years [95% confidence interval (95% CI): 1·64-2·76] and the incidence of stroke was 0·26/100 patient-years (95% CI: 0·07-0·46). The cumulative risk of CV by age 14 years was 26·0% (95% CI: 20·0-33·3%). Risk factors for CV were assessed by a Cox model encompassing linear multivariate modelling of longitudinal quantitative variables. Years per upper-airway obstruction [Hazard ratio (HR) = 1·47; 95% CI: 1·05-2·06] or bronchial obstruction (HR = 1·76; 95% CI: 1·49-2·08) and reticulocyte count (HR = 1·82 per 50 × 10(9) /l increase; 95% CI: 1·10-3·01) were independent risk factors whereas fetal haemoglobin level (HR = 0·68 per 5% increase; 95% CI: 0·48-0·96) was protective. Alpha-thalassaemia was not protective in multivariate analysis (ancillary analysis n = 209). Specific treatment for upper or lower-airway obstruction and indirect targeting of fetal haemoglobin and reticulocyte count by hydroxycarbamide could potentially reduce the risk of CV.
© 2016 John Wiley & Sons Ltd.

Entities:  

Keywords:  cerebral vasculopathy; children; cohort; respiratory abnormalities; sickle cell disease; transcranial doppler

Mesh:

Substances:

Year:  2016        PMID: 26728571     DOI: 10.1111/bjh.13916

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  10 in total

Review 1.  Advances in Understanding Ischemic Stroke Physiology and the Impact of Vasculopathy in Children With Sickle Cell Disease.

Authors:  Kristin P Guilliams; Melanie E Fields; Michael M Dowling
Journal:  Stroke       Date:  2019-02       Impact factor: 7.914

Review 2.  Fetal hemoglobin in sickle cell anemia.

Authors:  Martin H Steinberg
Journal:  Blood       Date:  2020-11-19       Impact factor: 22.113

Review 3.  Neurologic complications in children under five years with sickle cell disease.

Authors:  Aisha A Galadanci; Michael R DeBaun; Najibah A Galadanci
Journal:  Neurosci Lett       Date:  2019-04-27       Impact factor: 3.046

Review 4.  Genetic therapies for the first molecular disease.

Authors:  Phillip A Doerfler; Akshay Sharma; Jerlym S Porter; Yan Zheng; John F Tisdale; Mitchell J Weiss
Journal:  J Clin Invest       Date:  2021-04-15       Impact factor: 14.808

5.  Interleukin-10 haplotypes are not associated with acute cerebral ischemia or high-risk transcranial Doppler in a newborn cohort of 395 children with sickle cell anemia.

Authors:  André Rolim Belisário; Rahyssa Rodrigues Sales; Nayara Evelin Toledo; Cibele Velloso-Rodrigues; Célia Maria Silva; Marcos Borato Viana
Journal:  Rev Bras Hematol Hemoter       Date:  2017-02-21

Review 6.  Genetic, laboratory and clinical risk factors in the development of overt ischemic stroke in children with sickle cell disease.

Authors:  André Rolim Belisário; Célia Maria Silva; Cibele Velloso-Rodrigues; Marcos Borato Viana
Journal:  Hematol Transfus Cell Ther       Date:  2017-11-26

7.  Timed Average Mean Maximum Velocity (TAMMV) of Cerebral Blood Flow of Children and Adolescents with Sickle cell Disease: correlation with clinical and hematological profiles in country.

Authors:  Bartholomew Chukwu; Lyra Menezes; Thiago Fukuda; Jamary Filho; Marilda Goncalves
Journal:  Malawi Med J       Date:  2021-09       Impact factor: 0.875

8.  Associations of α-thalassemia and BCL11A with stroke in Nigerian, United States, and United Kingdom sickle cell anemia cohorts.

Authors:  Santosh L Saraf; Titilola S Akingbola; Binal N Shah; Chinedu A Ezekekwu; Omowunmi Sonubi; Xu Zhang; Lewis L Hsu; Mark T Gladwin; Roberto F Machado; Richard S Cooper; Victor R Gordeuk; Bamidele O Tayo
Journal:  Blood Adv       Date:  2017-04-25

9.  An Analysis of Racial and Ethnic Backgrounds Within the CASiRe International Cohort of Sickle Cell Disease Patients: Implications for Disease Phenotype and Clinical Research.

Authors:  Andrew D Campbell; Raffaella Colombatti; Biree Andemariam; Crawford Strunk; Immacolata Tartaglione; Connie M Piccone; Deepa Manwani; Eugenia Vicky Asare; Donna Boruchov; Fatimah Farooq; Rebekah Urbonya; Gifty Dankwah Boatemaa; Silverio Perrotta; Laura Sainati; Angela Rivers; Sudha Rao; William Zempsky; Fredericka Sey; Catherine Segbefia; Baba Inusa; Charles Antwi-Boasiako
Journal:  J Racial Ethn Health Disparities       Date:  2020-05-16

10.  Salbutamol Worsens the Autonomic Nervous System Dysfunction of Children With Sickle Cell Disease.

Authors:  Plamen Bokov; Houmam El Jurdi; Isabelle Denjoy; Claudine Peiffer; Noria Medjahdi; Laurent Holvoet; Malika Benkerrou; Christophe Delclaux
Journal:  Front Physiol       Date:  2020-02-26       Impact factor: 4.566

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.